PURPOSE: This systematic review aimed to assess the literature for management strategies and economic impact of salivary gland hypofunction and xerostomia induced by cancer therapies and to determine the quality of evidence-based management recommendations. METHODS: The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. For each article, two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results, and conclusions. RESULTS: Seventy-two interventional studies met the inclusion criteria. In addition, 49 intensity-modulated radiation therapy (IMRT) studies were included as a management strategy aiming for less salivary gland damage. Management guideline recommendations were drawn up for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. CONCLUSIONS: There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.
PURPOSE: This systematic review aimed to assess the literature for management strategies and economic impact of salivary gland hypofunction and xerostomia induced by cancer therapies and to determine the quality of evidence-based management recommendations. METHODS: The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. For each article, two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results, and conclusions. RESULTS: Seventy-two interventional studies met the inclusion criteria. In addition, 49 intensity-modulated radiation therapy (IMRT) studies were included as a management strategy aiming for less salivary gland damage. Management guideline recommendations were drawn up for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. CONCLUSIONS: There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.
Authors: Lorena Baccaglini; Michael T Brennan; Peter B Lockhart; Lauren L Patton Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 2007-03
Authors: Marc W Münter; Simone Hoffner; Holger Hof; Klaus K Herfarth; Uwe Haberkorn; Volker Rudat; Peter Huber; Jürgen Debus; Christian P Karger Journal: Int J Radiat Oncol Biol Phys Date: 2006-12-15 Impact factor: 7.038
Authors: Kauko Saarilahti; Mauri Kouri; Juhani Collan; Tuomo Hämäläinen; Timo Atula; Heikki Joensuu; Mikko Tenhunen Journal: Radiother Oncol Date: 2004-12-08 Impact factor: 6.280
Authors: Mervyn Gornitsky; George Shenouda; Khalil Sultanem; Howard Katz; Michael Hier; Martin Black; Ana M Velly Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 2004-07
Authors: F G LeVeque; M Montgomery; D Potter; M B Zimmer; J W Rieke; B W Steiger; S C Gallagher; C C Muscoplat Journal: J Clin Oncol Date: 1993-06 Impact factor: 44.544
Authors: Petter Wilberg; Adriani Kanellopoulos; Ellen Ruud; Marianne Jensen Hjermstad; Sophie Dorothea Fosså; Bente Brokstad Herlofson Journal: Support Care Cancer Date: 2015-09-12 Impact factor: 3.603
Authors: Arjan Vissink; James B Mitchell; Bruce J Baum; Kirsten H Limesand; Siri Beier Jensen; Philip C Fox; Linda S Elting; Johannes A Langendijk; Robert P Coppes; Mary E Reyland Journal: Int J Radiat Oncol Biol Phys Date: 2010-11-15 Impact factor: 7.038
Authors: Jyoti Roy; Blake M Warner; Falguni Basuli; Xiang Zhang; Karen Wong; Thomas Pranzatelli; Anita T Ton; John A Chiorini; Peter L Choyke; Frank I Lin; Elaine M Jagoda Journal: Cancer Biother Radiopharm Date: 2020-02-19 Impact factor: 3.099
Authors: Andrew D Shubin; Timothy J Felong; Brittany E Schutrum; Debria S L Joe; Catherine E Ovitt; Danielle S W Benoit Journal: Acta Biomater Date: 2016-12-27 Impact factor: 8.947
Authors: Pataje G S Prasanna; Deepa Narayanan; Kory Hallett; Eric J Bernhard; Mansoor M Ahmed; Gregory Evans; Bhadrasain Vikram; Michael Weingarten; C Norman Coleman Journal: Radiat Res Date: 2015-08-18 Impact factor: 2.841
Authors: Aviram Mizrachi; Ana P Cotrim; Nora Katabi; James B Mitchell; Marcel Verheij; Adriana Haimovitz-Friedman Journal: Radiat Res Date: 2016-07-26 Impact factor: 2.841